Tech Company Financing Transactions
Prosetta Biosciences Funding Round
Prosetta Biosciences, based in San Francisco, secured $31 million from Fred Alger Management and Takeda Ventures.
Transaction Overview
Company Name
Announced On
12/4/2015
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Series D
Investors
Fred Alger Management (Vishwanath Lingappa)
Takeda Ventures (Ceri Davies)
Proceeds Purpose
The net proceeds from the private placement will be used primarily for research and development, with an emphasis in the fields of central nervous system diseases and disorders, oncology, inflammation, antiinfectives, vaccines, animal health and biodefense, among other fields, and for working capital and general corporate purposes.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
670 5th St.
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Website
Email Address
Overview
Prosetta Biosciences, Inc. is a biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Vishwanath Lingappa
VP - Bus. Development
Jeffrey Swarz
Browse more venture capital transactions:
Prev: 12/3/2015: ORIC Pharmaceuticals venture capital transaction
Next: 12/4/2015: Icon Bioscience venture capital transaction
Share this article
Where The Data Comes From
We record tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs